Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: Results of secondary endpoints from a randomized, placebo-controlled trial

✍ Scribed by Hensen, J.; Howard, C.P.; Walter, V.; Thuren, T.

• Book ID: 121411222
• Publisher: Masson Editeur
• Year: 2013
• Tongue: French
• Weight: 582 KB
• Volume: 39
• Category: Article
• ISSN: 1262-3636
• DOI: 10.1016/j.diabet.2013.07.003